TOKYO -- Investment funds Curi RMB Capital and Oasis Management are contesting the pricing of Taisho Pharmaceutical Holdings' management buyout in court, Nikkei has learned, after failed negotiations over their forced divestment as minority shareholders.
Pharmaceuticals
Japan's Taisho Pharma faces claim over buyout price from Curi RMB, Oasis
Investment funds say tender offer undercut interest of minority shareholders
The tender offer price of 8,620 yen per share reflected a premium of over 50% for Taisho Pharma stock but still priced the company below book value. (Photo by Yutaka Miyaguchi)
Read Next
Latest on Pharmaceuticals
